People first
Pages are created to answer useful questions for GLP-1 users, not merely to capture search traffic or imitate another publisher.
Editorial policy
Useful content with clear health boundaries.
OurGLP1 content should help users understand routines, tracking, reminders, and questions to raise with clinicians.
Primary sources
News and health claims should link to the regulator, trial registry, research paper, safety notice, or other primary evidence whenever available.
Named responsibility
Published stories identify their author, publication date, material update date, and review status. Evidence summaries state clearly when they have not been medically reviewed.
Careful claims
We distinguish early research from approved clinical use and avoid guaranteed outcomes, unsupported advice, and undeclared brand or drug affiliations.
News, not prescribing
We report attributed findings, study details, regulatory decisions, and uncertainty. We do not rank medicines or tell readers which treatment to start, stop, request, or switch to.
AI-assisted drafts
Automation may help find sources, organise notes, or prepare a draft. It does not replace checking claims against the cited evidence or making an accountable editorial decision.
Corrections
Material errors are corrected promptly. Substantial changes should update the page date and explain the correction when readers could otherwise be misled.
Health boundary
Our content is general information, not personalised medical advice. Readers should not start, stop, or change medication based on an OurGLP1 article and should discuss treatment decisions with a qualified healthcare professional.
Current review model
OurGLP1 currently publishes educational evidence summaries without a physician reviewer. Each article carries this status prominently. We do not describe content as medically reviewed unless a named, appropriately qualified professional has reviewed the final version.